Your current location is:{Current column} >>Text
U.S. government to buy $1 billion more worth of Merck's COVID
{Current column}9People have watched
Introduction© Reuters. FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed b ...

By Manas Mishra
(Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc and partner Ridgeback Biotherapeutics, the companies said on Tuesday.
The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.
That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.
The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.
"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end," said Frank Clyburn, president of Merck's human health business.
President Joe Biden said on Friday that the United States had also secured millions of doses of Pfizer Inc (NYSE:PFE)'s rival antiviral drug, which was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.
The Pfizer negotiations were for a deal similar to the one with Merck - 1.7 million courses of the treatment upfront with an additional option for 3.3 million, a senior U.S. health official said on Tuesday, confirming a New York Times report.
Pfizer Chief Executive Officer Alfred Bourla said on Friday that the company plans to sell its treatment for around the same price for high-income countries as Merck, at roughly $700 for a course of therapy.
Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.
Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
Tags:
Related articles
Marvell shares rally on AI commentary; several brokers reiterate Top Idea status By
{Current column}- Marvell Technology (NASDAQ:) shares surged as much as 16% in pre-market Friday after the chipmake ...
Read moreAre Interactive Brokers Forex brokers regular and compliant?
{Current column}FTI's top 100 forex brokers you can refer to for selection. If it is not in the top 100, you sho ...
Read moreIs XM Forex Broker Legit or a Scam? A Detailed Review
{Current column}In the vast ocean of financial markets, choosing a reliable and legitimate Forex broker is one of th ...
Read more
Popular Articles
- Dow futures rise 15 pts; Walmart earnings, jobless claims in focus By
- Is Markets.com Forex Broker Legit or a Scam? A Detailed Review
- Is 51 Markets forex broker a regular one?
- Is Scope Markets forex broker a regular one?
- XRP, ADA and MATIC Are Altcoins to Watch This Coming Week By CoinEdition
- Are RoboForex Forex brokers regular and compliant?
Latest articles
-
Dow futures little changed as investors await corporate earnings By
-
Is BCR forex broker a regular one?
-
Are Exness Forex brokers regular and compliant?
-
Are Hantec Forex brokers regular and compliant?
-
Cryptoverse: Every frog has its day as pepe pops 7,000% By Reuters
-
A Complete Overview of Windsor Brokers: Is It a Scam or Legit?